Triazabutadiene molecules for use in applications. e.g., those involving fluorogenic molecules, e.g., triazabutadiene molecules configured to generate a fluorescent compound when combined with a second molecule, e.g., upon reaction with a tyrosine molecule or other appropriate molecule; and protected triazabutadiene molecules that are stable in acidic conditions and are adapted to release an active (e.g., acid-labile} triazabutadiene molecule upon appropriate conditions, and methods for producing and using said protected or releasable triazabutadiene molecules (and products of cleavage).

Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II)

##STR00001##

wherein X, X.sub.1, X.sub.2, X.sub.3, X.sub.4 and X.sub.5, R.sub.1 through R.sub.4 and R.sub.9 are as described.

Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II)

##STR00001##

wherein X, X.sub.1, X.sub.2, X.sub.3, X.sub.4 and X.sub.5, R.sub.1 through R.sub.4 and R.sub.9 are as described.

A thiazole derivative serving as a DHODH inhibitor, and applications thereof. The present invention specifically relates to a compound represented by formula I, a pharmaceutical composition containing the compound represented by formula (I), and applications of the compound in the preparation of drugs for treating diseases mediated by the DHODH or drugs for inhibiting the DHODH.

##STR00001##

A thiazole derivative serving as a DHODH inhibitor, and applications thereof. The present invention specifically relates to a compound represented by formula I, a pharmaceutical composition containing the compound represented by formula (I), and applications of the compound in the preparation of drugs for treating diseases mediated by the DHODH or drugs for inhibiting the DHODH.

##STR00001##

Provided are applications of a thiazole derivative in treating virus infection and in the preparation of drugs for treating virus infection. Specifically, provided are applications of a compound represented by formula (I) and a pharmaceutical composition comprising the compound represented by formula (I) in treating virus infection and in the preparation of drugs for treating virus infection:

##STR00001##

Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) ##STR00001##
wherein X, X.sub.1, X.sub.2, X.sub.3, X.sub.4 and X.sub.5, R.sub.1 through R.sub.4 and R.sub.9 are as described.

Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) ##STR00001##
wherein X, X.sub.1, X.sub.2, X.sub.3, X.sub.4 and X.sub.5, R.sub.1 through R.sub.4 and R.sub.9 are as described.

Disclosed ore substituted aminothiazoles, which can be used for, among other things, the treatment of tuberculosis, pharmaceutical compositions containing the same, and methods of using the same.

Disclosed ore substituted aminothiazoles, which can be used for, among other things, the treatment of tuberculosis, pharmaceutical compositions containing the same, and methods of using the same.